Oosthuizen Johannes Jacobus

Merck & Co., Inc. [ MRK ]

MERCK & CO., INC., 126 LINCOLN AVENUE

RAHWAY, NJ 07065

1. Name and Address of Reporting Person

Oosthuizen Johannes Jacobus

2. Issuer Name and Ticker or Trading Symbol

Merck & Co., Inc. [ MRK ]

3. Date of Earliest Transaction (MM/DD/YYYY)

11/7/2022

4. If Amendment, Date Original Filed (MM/DD/YYYY)

5. Relationship of Reporting Person(s) to Issuer

__ Director

__ 10% Owner

X Officer (give title below)

__ Other (specify below)

President, U.S. Market

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

__ Form filed by More Than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Trans. Date</th>
<th>3. Trans. Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>11/7/2022</td>
<td>M</td>
<td>14703 A</td>
<td>50</td>
<td>26046.881 D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/7/2022</td>
<td>M</td>
<td>17455 A</td>
<td>50</td>
<td>43501.881 D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/7/2022</td>
<td>M</td>
<td>13540 A</td>
<td>50</td>
<td>57041.881 D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>11/7/2022</td>
<td>M</td>
<td>7045 A</td>
<td>50</td>
<td>64086.881 D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$77.62</td>
<td>11/7/2022</td>
<td>M</td>
<td>17455</td>
<td>17455</td>
<td>5/2/2029</td>
<td>Common Stock</td>
<td>17455</td>
<td>$0</td>
<td>0</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$75.36</td>
<td>11/7/2022</td>
<td>M</td>
<td>13540</td>
<td>13540</td>
<td>5/1/2021</td>
<td>Common Stock</td>
<td>13540</td>
<td>$0</td>
<td>6773</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$73.73</td>
<td>11/7/2022</td>
<td>M</td>
<td>7045</td>
<td>7045</td>
<td>5/3/2031</td>
<td>Common Stock</td>
<td>7045</td>
<td>$0</td>
<td>14094</td>
</tr>
</tbody>
</table>

Explanation of Responses:

(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.3700 to $99.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

(2) Holdings include shares acquired in dividend reinvestment transactions.


Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oosthuizen Johannes Jacobus</td>
<td>Director 10% Owner Officer Other</td>
</tr>
</tbody>
</table>
Signatures

/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen 11/7/2022

Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.